Olyos Group has acquired a controlling stake in NewScience
December 2025 — Olyos Group has acquired a controlling stake in NewScience from its founders through a transaction structured in two stages, with the strategic objective of ultimately acquiring 100% of the company. The transaction forms part of NewScience’s international growth strategy and a gradual cash-out process for the founder, who intends to complete a full exit. Olyos intends to retain the management team through a put and call option mechanism and an earn-out linked to NewScience’s 2025 EBITDA.
Olyos, headquartered in France, has been controlled since 2023 by European private equity firm Motion Equity Partners. With over 75 years of history, Olyos is an international nutrition and health platform, generating US$150 million (€130 million) in annual revenues. Olyos’ strategy is based on a combination of organic and inorganic growth across its brands, supported by a scientific and pharmaceutical-driven approach. To date, the group has completed seven strategic acquisitions to expand its geographic footprint.
Founded over 15 years ago by Juan Pablo Salas, NewScience is a well-established company in the nutritional supplements market, with a strong presence across categories such as omega-3, probiotics, specialized magnesium, collagen, vitamins and minerals. The company is the market leader in omega-3 supplements. NewScience operates a fully integrated, asset-light business model, outsourcing manufacturing, packaging and quality control, while focusing on R&D, top-tier suppliers and a strong commercial strategy. This approach has enabled the company to establish a presence in more than 1,700 points of sale, as well as digital channels. NewScience has nationwide coverage in Chile, operations in Ecuador and international expansion plans currently underway.
Our role in the transaction
Oaklins’ team in Chile acted as the exclusive buy-side financial advisor to Olyos in the acquisition of a controlling stake in NewScience S.A. It provided strategic and financial advice throughout the transaction, including valuation analysis, transaction structuring and negotiations with the sellers. Oaklins’ French team supported the early stages of the transaction, including the introduction that led to the mandate and the initial connection with Olyos.
Talk to the deal team
Related deals
itemedical has been acquired by Halma
itemedical, a Netherlands-based provider of digital platforms that integrate real-time patient data and alarms from a wide range of medical devices to support clinical decision-making and workflow efficiency in hospitals, has been acquired by Halma plc, a global group of life-saving technology companies. The acquisition represents a milestone in itemedical’s development and provides a platform for its next phase of growth. By joining Halma’s healthcare sector as a business unit of Halma subsidiary Static Systems Group (SSG), itemedical will strengthen its position as a provider of digital hospital workflow solutions, benefiting from access to a global network of technology businesses, resources to accelerate innovation and opportunities to expand its international footprint.
Learn moreIndigo Capital has acquired a minority stake in Vivason
Indigo Capital has acquired a minority stake in Vivason, a leading network of hearing care centers, to support the company’s growth and enable management to increase its ownership stake.
Learn moreUKAT Group has acquired Bayberry Limited
UK Addiction Treatment (UKAT) Group, a leading UK provider of residential addiction, mental health and behavioral health treatment backed by Sullivan Street Partners, has acquired Bayberry Limited, a specialist mental health and wellbeing treatment provider. Joining UKAT enables Bayberry to preserve continuity of care for patients and referral partners, retain the strength of its clinical team and benefit from UKAT’s operational infrastructure, referral network and marketing channels. This partnership supports Bayberry’s next stage of development while preserving the qualities that differentiate its service offering.
Learn more